zhpsЖурнал прикладной спектроскопииZhurnal Prikladnoii Spektroskopii0514-7506B. I. Stepanov Institute of Physics of the National Academy of Scienceszhps-883Research ArticleАННОТАЦИИ АНГЛОЯЗЫЧНЫХ СТАТЕЙABSTRACTS ENGLISH-LANGUAGE ARTICLESУФ-спектрофотометрические методы определения противоракового лекарственного средства гидрохлорида эрлотиниба в нерасфасованных и таблетированных формахValidated uv spectrophotometric methods for the determination of anticancer drug erlotinib hydrochloride in bulk and tablet formulationsRathodR. D.RathodR. D.

Ширпур 425405

Shirpur 425405

RathodL. D.RathodL. D.

Ширпур 425405

Shirpur 425405

MundadaA. B.MundadaA. B.

Ширпур 425405

Shirpur 425405

nandmundadarcp@gmail.comPatelH. M.PatelH. M.

Ширпур 425405

Shirpur 425405

Институт фармацевтического образования и исследований ПателяDepartment of Pharmaceutical Chemistry, R. C. Patel Institute of Pharmaceutical Education and Research202126072021884667671Copyright © Rathod R.D., Rathod L.D., Mundada A.B., Patel H.M., 20212021Rathod R.D., Rathod L.D., Mundada A.B., Patel H.M.Rathod R.D., Rathod L.D., Mundada A.B., Patel H.M.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://zhps.ejournal.by/jour/article/view/883

Разработаны два простых и точных УФ-спектрофотометрических метода определения гидрохлорида эрлотиниба в нерасфасованных и таблетированных лекарственных формах по спектру нулевого порядка (метод I) и по площади под кривой ошибок нулевого порядка (метод II). Препарат растворяли в фосфатном буферном растворе (pH 7.4) и проводили измерения методами I и II при 228.20 и 224.20–230.20 нм. Для эрлотиниба данными методами обнаружена линейная зависимость в диапазоне концентраций 10–70 мкг/мл с коэффициентом корреляции R2 > 0.99. Методы показывают хорошую воспроизводимость и восстановление с RSD < 2% и точностью 98.54–101.39 и 98.08–99.83%. Пределы обнаружения (LOD) и количественного определения (LOQ) составляют 1.16, 3.51 и 21.41, 64.90 мкг/мл для обоих методов соответственно.

Two different simple, accurate, and precise UV spectrophotometric methods have been developed for the estimation of erlotinib hydrochloride in bulk and tablet forms by the zero-order (method I) and the zeroorder AUC (method II). The drug was dissolved in a phosphate buffer solution (pH 7.4), and at 228.20 nm the zero-order (method I) and at 224.20–230.20 nm the zero-order AUC (method II) were developed. For both methods, erlotinib has linearity in the concentration range 10–70 µg/mL, with a correlation coefficient R2  > 0.99. Both methods showed good reproducibility and recovery with %RSD less than 2 and an accuracy of 98.54–101.39 and 98.08–99.83%, respectively. The limit of detection (LOD) and limit of quantification (LOQ) were found to be 1.16, 3.51, and 21.41, 64.90 µg/mL, respectively, for both methods. 

гидрохлорид эрлотинибаУФ-спектрометрияспектр нулевого порядкаплощадь под кривой ошибок нулевого порядкапротивораковое средствоerlotinib hydrochlorideUV spectrometriczero orderAUCanticancerThe authors are thankful to the R.C. Patel Institute of Pharmaceutical Education and Research, Shirpur (M.S.), India for providing the required facilities to carry out this research work. The authors are thankful to MSN Laboratories Private Limited Unit-II, Telangana, for providing erlotinib hydrochloride as a gift sample.ReferencesG. U. Rani, B. Chandrasekhar, N. Devanna, J. Appl. Pharm. Sci., 1, No. 7, 176–179 (2011).G. U. Rani, B. Chandrasekhar, N. Devanna, J. Appl. Pharm. Sci., 1, No. 7, 176–179 (2011).V. K. Chakravarthy, D. G. Sankar, Rasayan J. Chem., 4, No. 2, 393–399 (2011).V. K. Chakravarthy, D. G. Sankar, Rasayan J. Chem., 4, No. 2, 393–399 (2011).C. Karunakara, U. Aparna, V. Chandregowda, C. G. Reddy, Anal. Sci., 28, No. 3, 305–308 (2012).C. Karunakara, U. Aparna, V. Chandregowda, C. G. Reddy, Anal. Sci., 28, No. 3, 305–308 (2012).S. T. Latha, S. A. Thangadurai, M. Jambulingam, K. Sereya, D. Kamalakannan, M. Anilkumar, Arab. J. Chem., 10, 1138–1144 (2017).S. T. Latha, S. A. Thangadurai, M. Jambulingam, K. Sereya, D. Kamalakannan, M. Anilkumar, Arab. J. Chem., 10, 1138–1144 (2017).V. S. Saravanan, B. M. Rao, J. Drug Deliv. Ther., 3, No. 1, 50–54 (2013).V. S. Saravanan, B. M. Rao, J. Drug Deliv. Ther., 3, No. 1, 50–54 (2013).S. Bolandnazar, A. Divsalar, H. Valizadeh, A. Khodaei, P. Zakeri-Milani, Adv. Pharm. Bull., 3, No. 2, 289 (2013).S. Bolandnazar, A. Divsalar, H. Valizadeh, A. Khodaei, P. Zakeri-Milani, Adv. Pharm. Bull., 3, No. 2, 289 (2013).E. R. Lepper, S. M. Swain, A. R. Tan, W. D. Figg, A. Sparreboom, J. Chromatogr. B, 796, No. 1, 181–188 (2003).E. R. Lepper, S. M. Swain, A. R. Tan, W. D. Figg, A. Sparreboom, J. Chromatogr. B, 796, No. 1, 181–188 (2003).S. S. Pujeri, A. M. A. Khader, J. Seetharamappa, Anal. Lett., 42, No. 12, 1855–1867 (2009).S. S. Pujeri, A. M. A. Khader, J. Seetharamappa, Anal. Lett., 42, No. 12, 1855–1867 (2009).Y. Zhen, A. Thomas-Schoemann, L. Sakji, P. Boudou-Rouquette, N. Dupin, L. Mortier, M. Vidal, F. Goldwasser, B. Blanchet, J. Chromatogr. B, 928, 93–97 (2013).Y. Zhen, A. Thomas-Schoemann, L. Sakji, P. Boudou-Rouquette, N. Dupin, L. Mortier, M. Vidal, F. Goldwasser, B. Blanchet, J. Chromatogr. B, 928, 93–97 (2013).A. Svedberg, H. Green, A. Vikström, J. Lundeberg, S. Vikingsson, J. Pharm. Biomed., 107, 186–195 (2015).A. Svedberg, H. Green, A. Vikström, J. Lundeberg, S. Vikingsson, J. Pharm. Biomed., 107, 186–195 (2015).A. V. Raju, A. R. Nemala, AJPCT, 1, No. 1, 83–97 (2013).A. V. Raju, A. R. Nemala, AJPCT, 1, No. 1, 83–97 (2013).I. Andriamanana, I. Gana, B. Duretz, A. Hulin, J. Chromatogr. B, 926, 83–91 (2013).I. Andriamanana, I. Gana, B. Duretz, A. Hulin, J. Chromatogr. B, 926, 83–91 (2013).S. R. Thappali, K. Varanasi, S. Veeraraghavan, R. Arla, S. Chennupati, Sci. Pharm., 80, No. 3, 633–646 (2012).S. R. Thappali, K. Varanasi, S. Veeraraghavan, R. Arla, S. Chennupati, Sci. Pharm., 80, No. 3, 633–646 (2012).J. Pan, X. Jiang, Y. L. Chen, Pharmaceutics, 2, No. 2, 105–118 (2010).J. Pan, X. Jiang, Y. L. Chen, Pharmaceutics, 2, No. 2, 105–118 (2010).L. Signor, E. Varesio, R. F. Staack, V. Starke, W. F. Richter, G. Hopfgartner, Int. J. Mass Spectrom., 42, No. 7, 900–909 (2007).L. Signor, E. Varesio, R. F. Staack, V. Starke, W. F. Richter, G. Hopfgartner, Int. J. Mass Spectrom., 42, No. 7, 900–909 (2007).M. Yasir, U. Sara, Int. J. Appl. Pharm. Sci., 6, No. 9, 128–131 (2014).M. Yasir, U. Sara, Int. J. Appl. Pharm. Sci., 6, No. 9, 128–131 (2014).S. Singh, N. Dubey, D. K. Jain, Asian J. Chem., 3, No. 4, 885–887 (2010).S. Singh, N. Dubey, D. K. Jain, Asian J. Chem., 3, No. 4, 885–887 (2010).V. L. Jadhav, A. S. Patil, S. R. Chaudhari, A. A. Shirkhedkar, JPTRM, 7, No. 1, 31–35 (2019).V. L. Jadhav, A. S. Patil, S. R. Chaudhari, A. A. Shirkhedkar, JPTRM, 7, No. 1, 31–35 (2019).V. K. Redasani, P. R. Patel, D. Y. Marathe, S. R. Chaudhari, A. A. Shirkhedkar, S. J. Surana, J. Chil. Chem. Soc., 63, No. 3, 4126–4134 (2018).V. K. Redasani, P. R. Patel, D. Y. Marathe, S. R. Chaudhari, A. A. Shirkhedkar, S. J. Surana, J. Chil. Chem. Soc., 63, No. 3, 4126–4134 (2018).A. G. Radhika, A. Singh, A. Sowmya, A. Haque, V. Bakshi, N. Boggula, Int. J. Pharm. Biol. Sci., 8, No. 4, 1002–1008 (2018).A. G. Radhika, A. Singh, A. Sowmya, A. Haque, V. Bakshi, N. Boggula, Int. J. Pharm. Biol. Sci., 8, No. 4, 1002–1008 (2018).S. P. Karpova, Int. J. Pharm. Sci. Res., 9, No. 8, 3556–3560 (2018). 22. Int. Conf. Harmonization (ICH) Q2R1: Validation of Analytical Procedure Methodology, USFDA federal register, 62, 27463 (1997).S. P. Karpova, Int. J. Pharm. Sci. Res., 9, No. 8, 3556–3560 (2018). 22. Int. Conf. Harmonization (ICH) Q2R1: Validation of Analytical Procedure Methodology, USFDA federal register, 62, 27463 (1997).A. H. Beckett, J. B. Stenlake, Practical Pharmaceutical Chemistry, CBS Publication and Distributors, New Delhi, 4th Ed., Part II, 275–277 (1997).A. H. Beckett, J. B. Stenlake, Practical Pharmaceutical Chemistry, CBS Publication and Distributors, New Delhi, 4th Ed., Part II, 275–277 (1997).

The authors declare that there are no conflicts of interest present.